{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:32:01Z","timestamp":1789140721802,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"STADAPHARM GmbH"},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["101095146"],"award-info":[{"award-number":["101095146"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and hypothesis<\/jats:title>\n                    <jats:p>Albuminuria is widely used to monitor chronic kidney disease (CKD) and treatment response but is subject to variability and primarily reflects glomerular injury. Urinary clusterin and epidermal growth factor (uEGF) are associated with tubular injury and repair, respectively, and may serve as mechanism-informed pharmacodynamic biomarkers. We investigated responses of urinary clusterin and uEGF to endothelin receptor antagonists (ERAs) and sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i), respectively, in CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated changes in urinary clusterin-to-creatinine ratio (uCLU\/Cr) and uEGF-to-creatinine ratio (uEGF\/Cr) in two randomized CKD trial populations. Effects of ERA on uCLU\/Cr and endothelin-1 (ET-1) were assessed during the atrasentan enrichment phase of SONAR (Study of Diabetic Nephropathy with Atrasentan), and effects of SGLT2i on uEGF\/Cr were examined in DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) across different CKD etiologies, diabetes status, and glycemic control. Associations between uEGF\/Cr and intrarenal EGF messenger RNA (mRNA) expression were examined using kidney biopsy single-cell RNA sequencing data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 6 weeks of treatment with atrasentan, uCLU\/Cr decreased by 46.3% (95% confidence interval [CI]: \u221257.8 to \u221237.1), while serum ET-1 increased by 23.4% (95% CI 19.2\u201327.4). There were no effects on serum clusterin and only a numerical decrease in urinary ET-1. Baseline uCLU\/Cr correlated significantly with urinary ET-1 (Pearson r = 0.65, P\u00a0&amp;lt;\u00a0.0001). In DAPA-CKD, dapagliflozin attenuated the decline in uEGF\/Cr over 1 year, with heterogeneity across CKD etiologies. Relative increases were greatest in diabetic kidney disease and absent in glomerulonephritis and hypertensive nephropathy. Similarly, effects were larger in those with type 2 diabetes and higher baseline HbA1c. Tubular EGF mRNA expression correlated positively with uEGF\/Cr.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Urinary clusterin and uEGF are mechanism-informed pharmacodynamic biomarkers reflecting distinct intrarenal pathways engaged by ERA and SGLT2i therapy, respectively. These biomarkers complement albuminuria by capturing tubular injury and repair, providing a more comprehensive biological assessment of treatment effects and heterogeneity in CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfag068","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:42:53Z","timestamp":1774010573000},"page":"ii50-ii58","source":"Crossref","is-referenced-by-count":3,"title":["Novel protein biomarkers for risk stratification and personalized medicine"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3983-5136","authenticated-orcid":false,"given":"Erik","family":"Moedt","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Ju","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viji","family":"Nair","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Bjornstad","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington School of Medicine , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kretzler","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J L","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2026082423262966700_bib1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","article-title":"Chronic kidney disease and the global public health agenda: an international consensus","volume":"20","author":"Francis","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"2026082423262966700_bib2","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"2026082423262966700_bib3","volume-title":"2025 USRDS Annual Data Report: epidemiology of kidney disease in the United States","author":"National Institutes of Health\u2014USRDS","year":"2025"},{"key":"2026082423262966700_bib4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.34067\/KID.0000000000000335","article-title":"International variability in the epidemiology, management, and outcomes of CKD and ESKD: a systematic review","volume":"5","author":"Freedberg","year":"2024","journal-title":"Kidney360"},{"key":"2026082423262966700_bib5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026082423262966700_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2026082423262966700_bib7","doi-asserted-by":"publisher","first-page":"i37","DOI":"10.1093\/ndt\/gfae214","article-title":"Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application","volume":"40","author":"Moedt","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026082423262966700_bib8","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"The Lancet"},{"key":"2026082423262966700_bib9","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"The Lancet"},{"key":"2026082423262966700_bib10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med"},{"key":"2026082423262966700_bib11","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1053\/j.ajkd.2018.04.023","article-title":"Biological variability of estimated GFR and albuminuria in CKD","volume":"72","author":"Waikar","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2026082423262966700_bib12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1053\/j.ajkd.2023.12.018","article-title":"Urine albumin-creatinine ratio variability in people with type 2 diabetes: clinical and research implications","volume":"84","author":"Rasaratnam","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026082423262966700_bib13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1053\/j.ajkd.2021.03.026","article-title":"The promise of tubule biomarkers in kidney disease: a review","volume":"78","author":"Ix","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2026082423262966700_bib14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers"},{"key":"2026082423262966700_bib15","doi-asserted-by":"publisher","first-page":"316ra193","DOI":"10.1126\/scitranslmed.aac7071","article-title":"Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker","volume":"7","author":"Ju","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026082423262966700_bib16","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/ki.1996.94","article-title":"Expression of epidermal growth factor and its receptor in normal and diseased human kidney: an immunohistochemical and in situ hybridization study","volume":"49","author":"Gesualdo","year":"1996","journal-title":"Kidney Int"},{"key":"2026082423262966700_bib17","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.3390\/cells11213416","article-title":"The role of the epidermal growth factor receptor in diabetic kidney disease","volume":"11","author":"Harris","year":"2022","journal-title":"Cells"},{"key":"2026082423262966700_bib18","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.kint.2023.07.007","article-title":"Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes","volume":"104","author":"Sen","year":"2023","journal-title":"Kidney Int"},{"key":"2026082423262966700_bib19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/ndt\/gfy314","article-title":"Associations of urinary epidermal growth factor and monocyte chemotactic protein-1 with kidney involvement in patients with diabetic kidney disease","volume":"35","author":"Wu","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2026082423262966700_bib20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.nefro.2022.10.003","article-title":"Urinary epidermal growth factor in kidney disease: a systematic review","volume":"43","author":"R\u00edos-Silva","year":"2023","journal-title":"Nefrolog\u00eda"},{"key":"2026082423262966700_bib21","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1016\/j.ekir.2024.08.004","article-title":"Associations of urine epidermal growth factor with kidney and cardiovascular outcomes in individuals with CKD in SPRINT","volume":"9","author":"Postalcioglu","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026082423262966700_bib22","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.0000001086","article-title":"Association of urinary epidermal growth factor with kidney outcomes and effects of SGLT2 inhibition","author":"Moedt","year":"2026","journal-title":"J Am Soc Nephrol"},{"key":"2026082423262966700_bib23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/FTD.0000000000000589","article-title":"Biomarkers of drug-induced kidney toxicity","volume":"41","author":"Griffin","year":"2019","journal-title":"Ther Drug Monit"},{"key":"2026082423262966700_bib24","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.ekir.2025.04.035","article-title":"Urinary clusterin is a biomarker of renal epithelial senescence and predicts human kidney disease progression","volume":"10","author":"Baird","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026082423262966700_bib25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nbt.1622","article-title":"Urinary clusterin, cystatin C, \u03b22-microglobulin and total protein as markers to detect drug-induced kidney injury","volume":"28","author":"Dieterle","year":"2010","journal-title":"Nat Biotechnol"},{"key":"2026082423262966700_bib26","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41467-026-68973-5","article-title":"Urinary clusterin: a biomarker of human kidney disease progression and response to the endothelin receptor antagonist atrasentan treatment","volume":"17","author":"Ju","year":"2026","journal-title":"Nat Commun"},{"key":"2026082423262966700_bib27","doi-asserted-by":"publisher","first-page":"vbac016","DOI":"10.1093\/bioadv\/vbac016","article-title":"decoupleR: ensemble of computational methods to infer biological activities from omics data","volume":"2","author":"Badia-i-Mompel","year":"2022","journal-title":"Bioinf Adv"},{"key":"2026082423262966700_bib28","doi-asserted-by":"publisher","first-page":"7851","DOI":"10.1038\/s41467-022-35519-4","article-title":"A balanced measure shows superior performance of pseudobulk methods in single-cell RNA-sequencing analysis","volume":"13","author":"Murphy","year":"2022","journal-title":"Nat Commun"},{"key":"2026082423262966700_bib29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1681\/ASN.2012040355","article-title":"Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD","volume":"24","author":"Dhaun","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2026082423262966700_bib30","volume-title":"Chronic kidney disease research","author":"Groningen UMC","year":"2026"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag068\/67499982\/gfag068.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/Supplement_2\/ii50\/67499982\/gfag068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/Supplement_2\/ii50\/67499982\/gfag068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:26:32Z","timestamp":1787628392000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/Supplement_2\/ii50\/8539740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":30,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2026,3,24]]},"published-print":{"date-parts":[[2026,8,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag068","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,3,24]]}}}